AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics
GET POWR RATINGS... FREE!
AGE Stock Summary
- With a price/sales ratio of 466.82, AGEX THERAPEUTICS INC has a higher such ratio than 99.09% of stocks in our set.
- AGE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.89% of US stocks.
- As for revenue growth, note that AGE's revenue has grown -91.48% over the past 12 months; that beats the revenue growth of merely 1.32% of US companies in our set.
- Stocks that are quantitatively similar to AGE, based on their financial statements, market capitalization, and price volatility, are MNKD, RDHL, APEN, HLLY, and DCFC.
- Visit AGE's SEC page to see the company's official filings. To visit the company's web site, go to www.agexinc.com.
AGE Valuation Summary
- AGE's EV/EBIT ratio is -5.5; this is 183.33% lower than that of the median Healthcare stock.
- AGE's price/sales ratio has moved up 396.8 over the prior 53 months.
Below are key valuation metrics over time for AGE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AGE | 2023-03-24 | 466.0 | -1.6 | -2.5 | -5.5 |
| AGE | 2023-03-23 | 458.5 | -1.6 | -2.5 | -5.4 |
| AGE | 2023-03-22 | 466.0 | -1.6 | -2.5 | -5.5 |
| AGE | 2023-03-21 | 435.8 | -1.5 | -2.3 | -5.3 |
| AGE | 2023-03-20 | 454.7 | -1.6 | -2.4 | -5.4 |
| AGE | 2023-03-17 | 464.2 | -1.6 | -2.5 | -5.5 |
AGE Stock Price Chart Interactive Chart >
AGE Price/Volume Stats
| Current price | $0.66 | 52-week high | $1.12 |
| Prev. close | $0.66 | 52-week low | $0.50 |
| Day low | $0.63 | Volume | 3,600 |
| Day high | $0.66 | Avg. volume | 18,253 |
| 50-day MA | $0.66 | Dividend yield | N/A |
| 200-day MA | $0.63 | Market Cap | 25.16M |
AgeX Therapeutics, Inc. (AGE) Company Bio
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
Latest AGE News From Around the Web
Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio |
AgeX Therapeutics Reports Third Quarter 2022 Financial ResultsALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022. |
AgeX Therapeutics Reports Second Quarter 2022 Financial ResultsALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022. |
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of DirectorsALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s |
AgeX Therapeutics Reports First Quarter 2022 Financial ResultsALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022. |
AGE Price Returns
| 1-mo | 11.92% |
| 3-mo | 19.59% |
| 6-mo | 13.93% |
| 1-year | -22.33% |
| 3-year | -17.30% |
| 5-year | N/A |
| YTD | 19.59% |
| 2022 | -49.37% |
| 2021 | -28.29% |
| 2020 | -16.48% |
| 2019 | -39.13% |
| 2018 | N/A |
Loading social stream, please wait...